Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) Operating Expenses (2020 - 2026)

GeneDx Holdings has reported Operating Expenses over the past 7 years, most recently at $94.4 million for Q1 2026.

  • Quarterly Operating Expenses rose 49.77% to $94.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $272.5 million through Mar 2026, up 52.87% year-over-year, with the annual reading at $222.8 million for FY2025, 48.33% up from the prior year.
  • Operating Expenses was $94.4 million for Q1 2026 at GeneDx Holdings, up from $71.4 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $98.5 million in Q2 2022 and troughed at $35.0 million in Q1 2024.
  • The 5-year median for Operating Expenses is $58.3 million (2023), against an average of $58.0 million.
  • The largest YoY upside for Operating Expenses was 296.8% in 2022 against a maximum downside of 56.17% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $67.6 million in 2022, then tumbled by 34.68% to $44.1 million in 2023, then fell by 10.01% to $39.7 million in 2024, then skyrocketed by 79.67% to $71.4 million in 2025, then soared by 32.26% to $94.4 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Operating Expenses are $94.4 million (Q1 2026), $71.4 million (Q4 2025), and $64.3 million (Q3 2025).